Skip to main content

Table 2 Phenotypic susceptibility and genotypic characterization of M. tuberculosis isolates with disputed rpoB mutations

From: Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis

Isolate Culture Clinical Phenotypic resistance Susceptibility Mutations detected inc embB pncA Spoligotyping Final resistance
no. no. specimen to anti-TB drugsb to PZAb rpoB katG315 inhA-RR mutation mutation lineage pattern
D1 5853/05 BALa INH + SM Not done H526N S315 T None None None Orphan INH + SM + RIF
D2 13,242/10 Sputum INH + EMB Not done D516Y S315 T None M306 V R2Pd EAI5/EAI3 INH + EMB + RIF + PZA
D3 10,268/11 Pleural fluid INH + SM Resistant H526N S315 T None M306 V H51P Orphan INH + SM + PZA + RIF + EMB
D4 13,341/16 Sputum INH + SM + EMB Susceptible S531C S315 T None M306 V None T1 Uganda INH + SM + EMB + RIF
  1. INH, isoniazid; SM, streptomycin; EMB, ethambutol; RIF, rifampicin, PZA, pyrazinamide
  2. HSR-rpoB, 81-base pair hot-spot region of rpoB gene; katG315, katG codon 315; inhA-RR, upstream regulatory region of inhA gene
  3. aBAL, bronchoalveolar lavage
  4. bThe susceptibility to anti-TB drugs was determined by MGIT 960 system
  5. cMutations in rpoB, katG codon 315 and inhA-regulatory region were detected by GenoType MTBDRplus assay and/or PCR-sequencing of respective loci
  6. dRepresents a novel mutation not described previously